NCT02474433

Brief Summary

This is a randomized trial, assessing Misoprostol efficacy in cervical preparation several hours prior to hysteroscopy, comparing the different routes of administration (PO/PV/buccal). Initial cervical dilatation will be assessed, as well as surgical ease of dilatation, time required to achieve dilatation and patient preference.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jul 2015

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 14, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 17, 2015

Completed
14 days until next milestone

Study Start

First participant enrolled

July 1, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2017

Completed
Last Updated

April 29, 2016

Status Verified

April 1, 2016

Enrollment Period

2 years

First QC Date

June 14, 2015

Last Update Submit

April 28, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Preoperative cervical width in centimeters

    Initial cervical dilatation assessed by performing cervical dilatation , beginning with a number 10 Hegar dilator and subsequently inserting smaller Hegar dilators until the dilator can pass through the internal os without resistance. The largest one to pass will consist the initial cervical width.

    intraoperative

Secondary Outcomes (5)

  • Time required to achieve cervical dilatation

    intraoperative

  • Ease of cervical dilatation

    intraoperative

  • Patient preference

    baseline

  • Adverse effects of medication

    baseline

  • Surgical complications

    intraoperative

Study Arms (3)

PO Misoprostol

ACTIVE COMPARATOR

Patients assigned to PO Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy

Drug: Misoprostol (Cytotec)

PV Misoprostol

ACTIVE COMPARATOR

Patients assigned to PV Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy

Drug: Misoprostol (Cytotec)

Buccal Misoprostol

ACTIVE COMPARATOR

Patients assigned to buccal Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy

Drug: Misoprostol (Cytotec)

Interventions

Buccal MisoprostolPO MisoprostolPV Misoprostol

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients admitted for elective hysteroscopy (diagnostic/surgical) at Wolfson Medical Center
  • Written consent supplied

You may not qualify if:

  • Contraindications to prostaglandin treatment (severe asthma, glaucoma, severe cardiac disease, renal failure)
  • Prostaglandin allergy
  • Pregnancy
  • Genital infection
  • Space-occupying lesion in the endocervical canal
  • Prior cervical surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Edith Wolfson Medical Center

Holon, Israel

RECRUITING

Related Publications (1)

  • Ganer Herman H, Kerner R, Gluck O, Feit H, Keidar R, Bar J, Sagiv R. Different Routes of Misoprostol for Same-Day Cervical Priming Prior to Operative Hysteroscopy: A Randomized Blinded Trial. J Minim Invasive Gynecol. 2017 Mar-Apr;24(3):455-460. doi: 10.1016/j.jmig.2016.12.024. Epub 2017 Jan 7.

MeSH Terms

Interventions

Misoprostol

Intervention Hierarchy (Ancestors)

Prostaglandins E, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological Factors

Central Study Contacts

Hadas Ganer Herman, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

June 14, 2015

First Posted

June 17, 2015

Study Start

July 1, 2015

Primary Completion

July 1, 2017

Study Completion

July 1, 2017

Last Updated

April 29, 2016

Record last verified: 2016-04

Locations